|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM333853423 |
| 003 |
DE-627 |
| 005 |
20250302175838.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108897
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1112.xml
|
| 035 |
|
|
|a (DE-627)NLM333853423
|
| 035 |
|
|
|a (NLM)34848357
|
| 035 |
|
|
|a (PII)S1521-6616(21)00234-5
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Magliulo, Daniel
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients
|b Effect of timing and immunologic parameters
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 21.01.2022
|
| 500 |
|
|
|a Date Revised 21.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Rituximab (RTX), an important therapeutic option for patients with rheumatic diseases, has been shown to reduce immune responses to various vaccines. We asked whether following SARS-CoV-2 vaccination, response rates in RTX treated patients are reduced and whether specific patient characteristics influence the responses. We recruited patients on chronic RTX therapy undergoing anti-SARS-CoV2 vaccination and measured the post-vaccination anti-spike IgG antibody levels. The median time from pre-vaccination RTX infusion to vaccination and from vaccination to the post-vaccination RTX infusion was 20.5 weeks and 7.2 weeks respectively. Only 36.5% of patients developed measurable titers of IgG anti-SARS-CoV-2 spike antibody after vaccination. Hypogammaglobulinemia (IgG and/or IgM) but not timing of vaccination, B cell numbers, or concomitant immune suppressive medications, correlated with sero-negativity (p = 0.004). Our results underscore the fact that even after B cell reconstitution, RTX induced chronic hypogammaglobulinemia significantly impairs the ability of the immune system to respond to SARS-CoV-2 vaccination
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Autoimmune diseases
|
| 650 |
|
4 |
|a B cells
|
| 650 |
|
4 |
|a COVID-19
|
| 650 |
|
4 |
|a Rituximab
|
| 650 |
|
4 |
|a Vaccination
|
| 650 |
|
7 |
|a Antibodies, Neutralizing
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Viral
|2 NLM
|
| 650 |
|
7 |
|a COVID-19 Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin M
|2 NLM
|
| 650 |
|
7 |
|a Rituximab
|2 NLM
|
| 650 |
|
7 |
|a 4F4X42SYQ6
|2 NLM
|
| 700 |
1 |
|
|a Wade, Stefanie D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kyttaris, Vasileios C
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 234(2022) vom: 07. Jan., Seite 108897
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:234
|g year:2022
|g day:07
|g month:01
|g pages:108897
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108897
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 234
|j 2022
|b 07
|c 01
|h 108897
|